What Is Orforglipron Approved For? Label Indications, Per the Research

The short answer from the regulatory literature

Orforglipron is a prescription medicine — an orally administered, small-molecule, non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor. Its regulatory milestone has been documented in the pharmacology literature: a 2026 article in Drugs recorded orforglipron's first approval and summarised the development programme that supported it (PMID 42479349). Because approved indication wording, population limits and conditions of use are set separately by each national regulator and are revised over time, the precise text of any given label is not something a literature summary can stand in for. The authoritative source is the current prescribing information issued in the relevant country, and any question about whether a particular person falls within an approved indication is one for a prescribing clinician.

What the published evidence base does show clearly is which conditions orforglipron was formally studied in during its phase 3 programme, because those trials define the therapeutic areas regulators were asked to consider. Those areas were chronic weight management in obesity and glycaemic control in type 2 diabetes. Every other proposed use discussed in reviews of the GLP-1 class remains investigational for this molecule.

Why orforglipron attracted regulatory attention

Reviews of the field framed orforglipron as a structural departure from the injectable GLP-1 receptor agonists. A 2025 review in Cardiovascular Diabetology — Endocrinology Reports described the shift "from needles to pills" and positioned orally available small molecules as a way to widen access to GLP-1 receptor pharmacology without peptide formulation constraints (PMID 41053816). A 2026 Endocrine Reviews overview of novel GLP-1-based medications for type 2 diabetes and obesity placed orforglipron among the agents reshaping that treatment landscape (PMID 41054801), and a 2025 commentary in Med characterised the arrival of an effective oral small molecule as a significant step for obesity pharmacotherapy (PMID 41389711). A 2025 systematic review of emerging obesity pharmacotherapies in Pharmacological Reviews catalogued orforglipron among agents advancing through late-stage development at that time (PMID 39952695).

The pivotal trials behind the indications studied

The table below lists the registrational-stage trials published in the peer-reviewed literature. Each row carries its own citation.

Obesity: what the 2025 NEJM trial reported

The 2025 New England Journal of Medicine obesity trial randomised adults with obesity to once-daily oral orforglipron at 6 mg, 12 mg or 36 mg or to placebo over 72 weeks, and researchers reported mean body-weight reductions of roughly 7.8% to 11.2% across the active groups compared with about 2.1% with placebo (PMID 40960239). The same report described greater weight reduction at higher dose levels, which is the pattern reviews of the class have repeatedly noted (PMID 41398455). These figures are trial averages across study populations with defined entry criteria; they describe what the study measured, not what any individual outside the trial would experience.

Type 2 diabetes: what the glycaemic trials reported

In the 2025 NEJM trial in early type 2 diabetes, researchers administered once-daily orforglipron at 3 mg, 12 mg or 36 mg against placebo for 40 weeks and reported HbA1c reductions of approximately 1.3 to 1.6 percentage points in the active groups versus roughly 0.1 percentage points with placebo, alongside reductions in body weight (PMID 40544435).

ACHIEVE-3, published in The Lancet in 2026, was a multinational, multicentre, open-label, randomised non-inferiority phase 3 trial that compared once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes; the investigators reported that orforglipron met the non-inferiority criterion for glycaemic efficacy in that comparison (PMID 41765029). ACHIEVE-5, published in JAMA in 2026, examined orforglipron added to titrated insulin glargine in adults with type 2 diabetes and reported greater reductions in HbA1c and body weight than the comparison arm in that setting (PMID 42251769). Together these trials map the glycaemic-control territory that regulators reviewed, spanning early disease, head-to-head comparison with another oral GLP-1 agent, and combination with basal insulin.

How to read "approved for" correctly

An approval is jurisdiction-specific, indication-specific and population-specific. Three distinctions matter when reading any summary of orforglipron's status:

• Approval exists versus approval everywhere. The 2026 Drugs report documented a first approval (PMID 42479349). A first approval in one country does not mean the medicine is authorised in another; separate regulators complete separate reviews on their own timelines.
• Studied versus approved. A condition appearing in a phase 3 programme is a condition a sponsor sought authorisation for — it is not automatically an approved indication, and regulators may authorise a narrower population than the one enrolled.
• Indication versus eligibility. Even within an approved indication, labels typically carry population criteria, contraindications and warnings. Whether those apply to a specific person is a clinical judgement, not a reading-comprehension exercise.

For those reasons, this page does not reproduce label text. The current prescribing information for the relevant country, and a prescribing clinician who can read it against an individual's history, are the appropriate references.

Uses discussed in the literature that are investigational, not approved

Reviews of GLP-1 receptor agonists as a class have explored applications well beyond weight and glycaemia, and it is important not to read class-level speculation as orforglipron label content. A 2025 article in Der Nervenarzt examined whether GLP-1 receptor agonists might have a role in psychiatric illness and treated that question as an open research area rather than established practice (PMID 40042613). Broader reviews of hormone-based anti-obesity medications have similarly separated agents with regulatory authorisation from those still in development, and have noted how quickly that boundary moves (PMID 39676791).

The following are examples of areas raised in class-level literature that are not established indications for orforglipron:

• Psychiatric and addiction-related applications, framed as a research question in a 2025 review (PMID 40042613).
• Other metabolic or cardiometabolic uses discussed in broad overviews of GLP-1-based medications without being specific label claims for this molecule (PMID 41054801).
• Populations not enrolled in the published phase 3 trials, such as groups outside the age or comorbidity criteria described in those reports (PMID 40960239).

Tolerability and Adverse Events: What Studies Report

Across the published trials, the dominant adverse-event signal was gastrointestinal. The 2025 NEJM obesity trial reported that nausea, vomiting, diarrhoea and constipation were the most common adverse events with orforglipron and that they were generally mild to moderate and most frequent during dose escalation (PMID 40960239). The 2025 NEJM trial in early type 2 diabetes described a comparable gastrointestinal profile, with discontinuations attributed in part to those events (PMID 40544435).

The 2026 Lancet comparison with oral semaglutide reported safety findings consistent with the GLP-1 receptor agonist class in adults with type 2 diabetes (PMID 41765029), and the 2026 JAMA insulin add-on trial reported on tolerability in the context of concurrent basal insulin therapy (PMID 42251769). Narrative reviews have summarised the class-wide pattern of dose-related gastrointestinal effects and the role of gradual escalation in mitigating them (PMID 41398455). Labelled warnings, contraindications and monitoring requirements are set by regulators and are not reproduced here.

What is still unknown from the published record

Several questions are not answered by the trials summarised above. Long-term cardiovascular outcome data for orforglipron specifically were not reported in the pivotal publications cited on this page. Durability of weight change beyond the published follow-up periods, and behaviour after discontinuation, were likewise outside the scope of those reports (PMID 40960239). Reviews of emerging obesity pharmacotherapy have consistently flagged comparative effectiveness, durability and access as open issues for the whole class (PMID 39952695).

Where to look for current indication wording

Approval status changes. The reliable checks are the regulator's own product database for the relevant country, the current prescribing information document, and a licensed prescriber who can interpret both. Literature summaries — including this one — lag behind label revisions by design.

For background on the molecule itself, the mechanism and the wider trial programme, see the PeptideU orforglipron overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician or other qualified prescriber about whether any medicine, including orforglipron, is appropriate for a given person. Nothing here describes how a medicine should be used, and no part of it substitutes for the approved prescribing information.

References

• Orforglipron: First Approval (Drugs, 2026)
• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (The New England Journal of Medicine, 2025)
• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (The New England Journal of Medicine, 2025)
• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) (Lancet, 2026)
• Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial (JAMA, 2026)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• From needles to pills: oral GLP-1 therapy enters the obesity arena (Cardiovascular Diabetology. Endocrinology Reports, 2025)
• Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes (Cardiology in Review, 2025)
• One small molecule for man, one giant leap for mankind with obesity (Med, 2025)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article (Indian Journal of Endocrinology and Metabolism, 2024)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)